Lv11
50 积分 2025-04-23 加入
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
31分钟前
待确认
Current controversies in the use of Oncotype DX in early breast cancer
11个月前
已完结